DOCS vs DVA Stock Comparison
Compare DOCS and DVA across AIQ Score, fundamentals, valuation, momentum, risk, analyst expectations and current market evidence.
What is the main difference between DOCS and DVA?
DVA leads the current stock comparison as DaVita Inc., with the clearest separation coming from value and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Doximity, Inc. vs DaVita Inc.
DVA leads
DVA leads by 1 AIQ points, primarily on Value and Momentum, having only recently taken the lead back from DOCS.
Fragile: 3 of 6 evidence groups support DVA, the lead recently changed hands, and its signal state is cleanly positive.
Doximity, Inc.
DaVita Inc.
The Algovestiq AIQ Score currently favors DVA over DOCS, 58 versus 57 as of Sep 11, 2026. DVA's advantage is driven primarily by stronger value and momentum, while DOCS holds the stronger quality profile. DVA also shows the weaker technical structure relative to its 50-day moving average. 3 of 6 covered evidence groups favor DVA today, and the comparison is rated Fragile on stability: the AIQ gap is narrow at 1 points. DVA lead: Reversed — DOCS led by 16 AIQ points 30 sessions ago; DVA now leads by 1.
Compare Doximity, Inc. and DaVita Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price-return comparison using available daily close history.
Total return comparison
Growth of $10,000
Based on available close-price history. Distribution reinvestment is not added unless already reflected in the source series.
Compare DOCS and DVA against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Quality77 vs 44DOCS +33
- Value46 vs 68DVA +22
- Momentum47 vs 64DVA +17
- Risk Resilience56 vs 56Even
3 of 6 evidence groups favor DVA. DVA’s edge is concentrated in value and momentum; DOCS keeps a meaningful quality edge.
What changed since the last close
Latest scored session 2026-09-10, compared against the prior scored session 2026-09-09.
Largest factor move: Momentum +2
No new signals fired.
Largest factor move: Momentum +1
No new signals fired.
DVA's lead was unchanged in the latest snapshot.
Deeper signal detail for each name lives on its own signals page — DOCS and DVA both carry a full feed there.
The central trade-off
DVA (DaVita Inc.): the stronger current systematic profile, led by value and momentum.
DOCS (Doximity, Inc.): the counter-case, on quality, fundamentals — but at materially higher volatility, 54.2% against 21.6%.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
DVADVA on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
DVADVA on combined revenue and EPS growth.
Value
DVADVA on the peer-relative Value factor, by 22 points.
Momentum
DVADVA on the Momentum factor, by 17 points.
Lower downside
DVADVA carries the lower 1-month annualized volatility.
Analyst upside
DVADVA on implied upside to the consensus price target.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | DOCS | DVA | Note |
|---|---|---|---|
| Implied upside to target | +6.3% | +25.2% | DVA has more room |
| Target dispersion | +84.6% | +33.4% | Lower is tighter analyst agreement |
| Consensus | Buy | Hold | Context, not a primary driver |
| Analysts covering | 14 | 6 | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
3 of 6 covered evidence groups favor DVA. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | Even | 57 vs 58 |
| Fundamentals | DOCSon balance | revenue growth 7.7% vs 4.1%; EPS growth 30% vs 39.9%; TTM ROE 17% vs -123.6%; gross margin 88.1% vs 31%; operating margin 29.6% vs 15.1% — DOCS takes 4 of 5 decided legs, not all of them |
| Valuation | DVA | Value 46 vs 68 |
| Technicals | DVA | Price vs 50-day 8.7% vs -11.9%; vs 200-day -13.4% vs 9.9% |
| Risk Resilience | Even | Risk Resilience 56 vs 56 |
| Analyst expectations | DVA | Target upside 6.3% vs 25.2% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of DOCS and DVA and are excluded from the count.
AIQ Decision Stability
The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.
- The AIQ gap is narrow at 1 points. (argues the conclusion is provisional)
- Only 3 of 6 covered evidence groups agree. (argues the conclusion is provisional)
- The lead has already changed hands inside the comparison window. (argues the conclusion is provisional)
- The leader's signal state is cleanly positive. (supports the conclusion holding)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on DVA.
How the comparison changed
119 daily snapshots · May 4 – Sep 10DVA lead: Reversed — DOCS led by 16 AIQ points 30 sessions ago; DVA now leads by 1.
- Today
- DVA +1
- 57 vs 58
- 7 sessions ago
- DOCS +3
- 62 vs 59
- 30 sessions ago
- DOCS +16
- 61 vs 45
- 90 sessions ago
- Level
- 63 vs 63
The lead changed hands 8 times in this window, most recently on Sep 9 when DVA moved ahead of DOCS.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
0 bullish / 2 bearish / 2 neutral
- Death Cross Active — bearish, trend, long horizon (21.25%)
- Bollinger Band Squeeze — neutral, volatility, short horizon
- ATR Expansion - Breakout Mode — neutral, volatility, short horizon (5.35%)
2 bullish / 0 bearish
- Golden Cross Active — bullish, trend, long horizon (24.79%)
- MACD Bullish Crossover — bullish, momentum, short horizon
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +3.52%, AIQ 0 points).
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +0.12%, AIQ 0 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1DOCS closes the Value gap — currently 22 points behind, the largest single contributor to DVA's edge.
- 2DOCS's Death Cross Active resolves — a bearish trend rule currently active against it.
- 3DVA's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict.
- 4A regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
DOCS leads on balance| Metric | DOCS | DVA |
|---|---|---|
| Revenue growth (YoY) | 7.7% | 4.1% |
| EPS growth (YoY) | 30% | 39.9% |
| Gross margin | 88.1% | 31% |
| Operating margin | 29.6% | 15.1% |
| Return on equity (TTM) | 17% | -123.6% |
| Debt to equity | 0.01 | -14.09 |
Performance
DVA leads 5 of 6 windows| Metric | DOCS | DVA |
|---|---|---|
| 1 week (5 sessions) | -6.1% | 1.1% |
| 1 month (20 sessions) | -1.1% | -0.1% |
| 3 months (63 sessions) | 22.1% | -8.7% |
| 6 months (126 sessions) | 0.3% | 17.1% |
| Year to date | -44.2% | 59.6% |
| 1 year (252 sessions) | -64.5% | 34.8% |
Technicals
DVA has the stronger structure| Metric | DOCS | DVA |
|---|---|---|
| RSI (14) | 42.1 | 59.6 |
| ADX (14) | 35.7 | 30.8 |
| Price vs 50-day | 8.7% | -11.9% |
| Price vs 200-day | -13.4% | 9.9% |
| Volatility (1M, annualized) | 54.2% | 21.6% |
Risk
Split| Metric | DOCS | DVA |
|---|---|---|
| Beta | 0.63 | 0.04 |
| Sharpe ratio | -1.38 | 0.76 |
| Sortino ratio | -1.76 | 1.17 |
| Max drawdown | -76% | -27.9% |
| Current drawdown | -67.1% | -24.8% |
| Annualized volatility | 63.6% | 45.2% |
| Value at risk (95%) | -5.6% | -2.8% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, DOCS or DVA?
On the Algovestiq AIQ Score, DVA is the stronger of the two as of Sep 11, 2026, scoring 58 against DOCS's 57. The edge comes from value and momentum. DOCS is not without a case — it holds the better quality profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is DOCS or DVA the better buy right now?
DVA carries the stronger systematic profile as of Sep 11, 2026, and the comparison is rated Fragile — 3 of 6 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: the AIQ gap is narrow at 1 points. Treat the lead as provisional.
Why does the AIQ Score favor DVA over DOCS?
The composite weights Quality, Value, Momentum and Risk Resilience. DOCS leads Quality by 33 points; DVA leads Value by 22 points; DVA leads Momentum by 17 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, DOCS or DVA?
Analyst price targets imply +6.3% upside for DOCS and +25.2% for DVA, so the Street currently favors DVA. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, DOCS or DVA?
DVA is the better-valued of the two on the peer-relative Value factor. DVA on the peer-relative Value factor, by 22 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, DOCS or DVA?
DVA on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, DOCS or DVA?
DVA on the Momentum factor, by 17 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, DOCS or DVA?
DVA is the more resilient of the two, so the other name carries the higher downside risk. DVA carries the lower 1-month annualized volatility. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is DOCS more profitable than DVA?
DOCS leads on the comparable margin measures — gross margin 88.1% vs 31%; operating margin 29.6% vs 15.1%; ttm roe 17% vs -123.6%.
Is DVA's lead over DOCS getting stronger or weaker?
DVA lead: Reversed — DOCS led by 16 AIQ points 30 sessions ago; DVA now leads by 1. This is measured from 119 daily comparison snapshots between 2026-05-04 and 2026-09-10. The lead has changed hands 8 times in that window, most recently on 2026-09-09, when DVA moved ahead of DOCS.
What would change the DOCS vs DVA verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: DOCS closes the Value gap — currently 22 points behind, the largest single contributor to DVA's edge; DOCS's Death Cross Active resolves — a bearish trend rule currently active against it; DVA's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict; a regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.
What do the current signals say about DOCS and DVA?
DOCS: 0 bullish / 2 bearish / 2 neutral. DVA: 2 bullish / 0 bearish. The most decision-relevant rule on DOCS is Death Cross Active (bearish, long horizon). On DVA it is Golden Cross Active (bullish, long horizon).
Compare DOCS and DVA with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.